Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

New Simoa® phospho-Tau 181 (pTau-181) Blood Test Discovered for Alzheimer’s Disease

Quanterix Corporation discovers new Blood-Based pTau-181 Assay for Alzheimer’s Disease.  The Simoa® phospho-Tau 181 (pTau-181) blood test will be used for diagnostic evaluation of Alzheimer’s Disease (AD).

With the use of HD-X immunoassay system, the pTau-181 concentration in human serum and plasma with the help of blood-based assay. The test is applicable for adult patients with the age of 50 years and above 50 years with cognitive impairment assessed for AD. Moreover, for other causes of cognitive decline it is used as an diagnostic evaluation for AD. In order to obtain final clinical diagnosis, the assay will be interpreted along with other diagnostic tools.

This technology has the ability to detect low-abundance markers in a blood sample which unlocks the possibility of earlier, more accessible, non-invasive diagnosis of disease, including AD.

U.S. Food and Drug Administration (FDA) grants breakthrough device designation for Blood-Based pTau-181 Assay for Alzheimer’s Disease.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024